Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Aarthritis (RA)
- Conditions
- First Posted Date
- 2018-06-18
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- UCB Biopharma SRL
- Registration Number
- NCT03559686
CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)
- Conditions
- First Posted Date
- 2018-06-18
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- UCB Biopharma SRL
- Registration Number
- NCT03559660
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-05-25
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 743
- Registration Number
- NCT03536884
- Locations
- 🇩🇪
Ps0015 222, Tuebingen, Germany
🇵🇱Ps0015 355, Bialystok, Poland
🇹🇷Ps0015 763, Gaziantep, Turkey
Compassionate Use Program With Brivaracetam for the Treatment of Patients With Epilepsy
- Conditions
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- UCB Biopharma SRL
- Registration Number
- NCT03532516
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 478
- Registration Number
- NCT03412747
- Locations
- 🇺🇸
Ps0008 905, Overland Park, Kansas, United States
🇨🇳Ps0008 755, Taipei, Taiwan
🇭🇺Ps0008 260, Szeged, Hungary
A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-01-25
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 435
- Registration Number
- NCT03410992
- Locations
- 🇵🇱
Ps0013 361, Białystok, Poland
🇷🇺Ps0013 402, Moscow, Russian Federation
🇵🇱Ps0013 359, Katowice, Poland
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 567
- Registration Number
- NCT03370133
- Locations
- 🇭🇺
Ps0009 253, Orosháza, Hungary
🇯🇵Ps0009 607, Chiyoda, Japan
🇯🇵Ps0009 620, Hamamatsu, Japan
Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2021-12-29
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 406
- Registration Number
- NCT03370120
- Locations
- 🇺🇸
Ep0093 645, Golden Valley, Minnesota, United States
🇺🇸Ep0093 806, Hackensack, New Jersey, United States
🇺🇸Ep0093 802, Philadelphia, Pennsylvania, United States
A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis
- First Posted Date
- 2017-11-28
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 255
- Registration Number
- NCT03355573
- Locations
- 🇵🇱
As0009 453, Elblag, Poland
🇨🇿As0009 201, Praha 4, Czechia
🇵🇱As0009 460, Wroclaw, Poland
A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis
- First Posted Date
- 2017-11-20
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 184
- Registration Number
- NCT03347110
- Locations
- 🇨🇿
Pa0009 205, Brno, Czechia
🇨🇿Pa0009 207, Olomouc, Czechia
🇺🇸Pa0009 013, Mesquite, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath